12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
40 citations
,
July 2023 in “Clinical Pharmacology & Therapeutics” Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.
3 citations
,
October 1994 in “Journal of Dermatological Science” The new antibody, TYHF-1, specifically targets certain hair-related structures.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
88 citations
,
August 2019 in “Nature communications” Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
8 citations
,
August 2025 in “Journal of Translational Medicine” CD44 signaling can help heal wounds without scars.
32 citations
,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
16 citations
,
April 2024 in “Proceedings of the National Academy of Sciences” HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
January 2025 in “Iraqi Journal of Science” PDCD4 protein levels, affected by genetics and breastfeeding, may predict breast cancer treatment response.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
4 citations
,
June 2025 in “MedComm” PROTACs show promise for cancer treatment, but designing them effectively is challenging.
25 citations
,
May 2017 in “InTech eBooks” Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.
May 2022 in “Голова и шея.” Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
1 citations
,
October 2023 in “Life science alliance” Pantethine may boost the immune system's ability to fight sarcoma.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
23 citations
,
October 2012 in “ChemistryOpen” Probe detects finasteride with high selectivity and low detection limit.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
11 citations
,
September 2024 in “Journal of Advanced Research” 3D-bioprinting models of pancreatic cancer could help personalize treatments but need more testing.
7 citations
,
February 2010 in “British Journal of Dermatology” A woman with a rare autoimmune disorder had a blister on her eye and unique immune reaction, which was effectively treated with medication.
March 2024 in “Poster presentations” A woman with lupus and Kikuchi-Fujimoto disease improved with treatment.
October 2025 in “Cell Death and Disease” CD271 is crucial for maintaining healthy skin and preventing inflammation.
March 2023 in “International Journal of Trichology” A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.